Ozempic Manufacturing, Supply, and Shortage History

How Ozempic Is Made: The Semaglutide Production Process

Semaglutide is a biologic peptide, not a small-molecule pill pressed in a tablet machine. Manufacturing it requires genetically engineered yeast, multi-step purification, and strict quality controls that make rapid scale-up difficult.

Recombinant Fermentation

Novo Nordisk produces the semaglutide peptide backbone using Saccharomyces cerevisiae (baker's yeast) modified through recombinant DNA technology. The yeast cells are cultured in large stainless-steel bioreactors at the company's Kalundborg, Denmark facility, one of the largest insulin and peptide manufacturing complexes in the world. During fermentation, the yeast expresses a GLP-1 analog precursor protein that is then harvested from the culture medium.

Chemical Modification and Purification

After fermentation, the precursor undergoes chemical acylation. A C-18 fatty diacid chain is attached to the peptide at position 26 (lysine), giving semaglutide its prolonged half-life of approximately 7 days. This albumin-binding side chain is what allows once-weekly dosing rather than the twice-daily injections required by native GLP-1. The modified peptide then passes through multiple chromatography and filtration steps to reach pharmaceutical-grade purity exceeding 95%.

Fill-Finish and Device Assembly

The purified semaglutide solution is filled into glass cartridges, which are assembled into Ozempic's proprietary FlexTouch prefilled pens. Each pen contains multiple doses. Fill-finish operations occur at both the Kalundborg site and the Clayton, North Carolina facility. The entire manufacturing cycle from initial fermentation batch to a finished, quality-released pen takes roughly 12 months, a timeline Novo Nordisk has confirmed in investor communications.

This 12-month lead time is the central constraint. When demand doubles in 18 months, no manufacturing decision can close that gap quickly.

Why Ozempic Went Into Shortage

The Ozempic shortage that began in 2022 was not caused by a manufacturing defect, contamination, or supply chain breakdown. It was caused by demand that grew faster than any biologics factory could physically produce.

The Off-Label Demand Surge

Ozempic was approved by the FDA in December 2017 for glycemic control in type 2 diabetes. Between 2018 and 2021, prescriptions grew steadily but predictably. The inflection point came in 2022, when social media coverage, celebrity endorsements, and growing clinical evidence for semaglutide's weight-loss effects (demonstrated in the STEP trial program with the higher-dose Wegovy formulation) drove a massive increase in off-label prescribing for obesity.

Total semaglutide prescriptions in the United States rose from approximately 1.5 million in Q4 2021 to over 5 million by Q4 2023, according to IQVIA prescription tracking data. A significant fraction of new Ozempic prescriptions were written for patients without type 2 diabetes.

FDA Shortage Listing Timeline

The FDA first listed Ozempic on its Drug Shortage Database in March 2022, initially affecting the 0.25 mg and 0.5 mg starter doses. By mid-2023, all dose strengths (0.25 mg, 0.5 mg, 1 mg, and 2 mg) appeared intermittently on the shortage list. The FDA categorized the cause as "demand increase for the drug" rather than a manufacturing or quality issue.

Impact on Diabetes Patients

The shortage created a two-tier access problem. Patients with type 2 diabetes who had been stable on Ozempic for months or years found themselves unable to refill prescriptions. Meanwhile, new-start patients prescribed Ozempic off-label for weight management were competing for the same limited supply. The American Diabetes Association issued a public statement in 2023 emphasizing that GLP-1 receptor agonists should remain available for their approved diabetes indication.

Pharmacies reported allocation limits, with some receiving only 50 to 70% of their ordered Ozempic supply. Several large health systems implemented prescribing restrictions, limiting new Ozempic starts to patients with documented A1C levels above 7.0%.

Novo Nordisk's Manufacturing Expansion

Novo Nordisk recognized the supply-demand mismatch and committed the largest capital investment in the company's 101-year history to close the gap.

The $18 Billion Build-Out

Between 2023 and 2026, Novo Nordisk announced cumulative investments exceeding $18 billion in manufacturing infrastructure. The major projects include:

• Kalundborg expansion (Denmark): a new active pharmaceutical ingredient (API) facility capable of roughly doubling semaglutide bulk production, with initial output expected in late 2025
• Clayton, North Carolina (USA): a $2.3 billion fill-finish expansion adding new production lines for prefilled pens and autoinjectors
• Chartres, France: acquisition and conversion of a Catalent facility for additional fill-finish capacity
• Odense, Denmark: a new production site focused on oral semaglutide (Rybelsus) to shift some demand away from injectable formulations

Why Biologics Capacity Cannot Be Built Quickly

Adding a new fermentation line is not like adding a new assembly line for cars. Bioreactor vessels must be custom-fabricated, installed in cleanroom environments, validated by internal quality teams, and then inspected by regulators. A single bioreactor validation campaign can take 6 to 9 months. After that, the 12-month production cycle begins before a single dose reaches a pharmacy shelf.

Dr. Martin Holst Lange, Novo Nordisk's former executive vice president of development, described the constraint in a 2023 investor briefing: "You cannot accelerate biology. The yeast grows at the rate the yeast grows."

Parallel Strategies to Relieve Pressure

Beyond building new factories, Novo Nordisk pursued several parallel supply strategies:

• Prioritizing existing capacity: the company shifted some manufacturing lines from older products (liraglutide) toward semaglutide
• Geographic allocation adjustments: supply was redistributed across markets, with the United States receiving a larger share of global output
• Wegovy separation: by scaling up dedicated Wegovy (semaglutide 2.4 mg for obesity) production, Novo Nordisk aimed to reduce off-label demand on the Ozempic supply chain
• Oral semaglutide promotion: increased marketing of Rybelsus (oral semaglutide, 7 mg and 14 mg tablets) as an alternative for eligible T2D patients

How Semaglutide Works: Mechanism of Action

Understanding why semaglutide is difficult to manufacture starts with understanding what the molecule does. It is not a simple chemical compound. It is an engineered peptide that mimics a human hormone.

GLP-1 Receptor Agonism

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Native GLP-1 is an incretin hormone released by L-cells in the small intestine after eating. It stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it promotes insulin release only when blood sugar is elevated. This glucose-dependent mechanism is why GLP-1 agonists carry a lower risk of hypoglycemia compared to sulfonylureas or exogenous insulin.

Structural Modifications for Weekly Dosing

Native human GLP-1 has a plasma half-life of roughly 2 minutes. It is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide overcomes this through three structural modifications:

1. An amino acid substitution at position 8 (alanine to alpha-aminoisobutyric acid) that resists DPP-4 cleavage
2. An amino acid substitution at position 34 (lysine to arginine) that prevents fatty acid attachment at the wrong site
3. A C-18 fatty diacid spacer attached at position 26 that binds to serum albumin, shielding the peptide from renal clearance

These changes extend the half-life to approximately 168 hours (7 days), enabling once-weekly subcutaneous injection.

Effects Beyond Blood Sugar

Semaglutide acts on GLP-1 receptors in the pancreas, gut, and brain. In the hypothalamus, it reduces appetite and increases satiety signaling, which is the mechanism behind its weight-loss effects. In the SUSTAIN-7 trial (N=1,201), patients with type 2 diabetes receiving semaglutide 1 mg lost a mean of 5.5 to 7.3 kg over 40 weeks, significantly more than those receiving dulaglutide. Semaglutide also slows gastric emptying, contributing to post-meal glucose reduction and the nausea that is its most common side effect.

The Compounding Controversy

The Ozempic shortage opened a regulatory debate about compounded semaglutide that has affected both patients and manufacturers.

Section 503A and 503B Compounding

Under the Federal Food, Drug, and Cosmetic Act, Section 503A allows individual pharmacies and Section 503B allows outsourcing facilities to compound copies of FDA-approved drugs when those drugs appear on the shortage list. Beginning in mid-2022, hundreds of compounding pharmacies began producing semaglutide sodium or semaglutide acetate salt forms for injection.

Quality and Safety Concerns

The FDA issued multiple warnings about compounded semaglutide products, citing several concerns:

• Compounded versions use semaglutide salt forms (sodium, acetate) that are chemically distinct from the base form in Ozempic and have not undergone FDA efficacy or safety review
• Adverse event reports linked to compounded semaglutide included dosing errors, sterility failures, and unexpected side effects
• Some compounders marketed their products directly to consumers without requiring prescriptions from licensed providers

By late 2024, as Novo Nordisk's supply improved for certain dose strengths, the FDA began considering removal of semaglutide from the shortage list, which would eliminate the legal basis for 503A and 503B compounding. This triggered legal challenges from compounding pharmacies and patient advocacy groups.

Current Regulatory Status

As of early 2026, the regulatory field for compounded semaglutide remains in flux. The FDA has taken enforcement actions against specific compounders while the broader policy question (whether semaglutide should remain on or be removed from the shortage list) continues to involve litigation. Patients who are currently using compounded semaglutide should discuss transition planning with their prescribing clinician.

Current Supply Status and Outlook

The Ozempic supply situation has improved measurably since the peak shortage period of mid-2023, though intermittent constraints persist for specific dose strengths.

Dose-Specific Availability

As of early 2026, the 0.5 mg and 1 mg dose strengths have been the most consistently available, reflecting Novo Nordisk's prioritization of maintenance doses over starter doses. The 0.25 mg starter dose and the 2 mg dose (approved by FDA in March 2022) have experienced more intermittent availability. Patients initiating therapy may still encounter short delays at the pharmacy level.

What Patients Should Do During Supply Disruptions

The American Association of Clinical Endocrinology (AACE) and the American Diabetes Association have both issued guidance for managing GLP-1 agonist supply disruptions:

• Do not split or share pens between patients
• If your prescribed dose is unavailable, contact your clinician about a temporary switch to another GLP-1 agonist (dulaglutide, liraglutide) rather than skipping doses entirely
• Patients with type 2 diabetes should have their A1C monitored more frequently during any treatment interruption
• Do not substitute compounded semaglutide without discussing risks with a licensed prescriber

Production Projections

Novo Nordisk has projected that its combined semaglutide production capacity (across Ozempic, Wegovy, and Rybelsus) will approximately triple between 2023 and 2027 as new facilities come online. The Kalundborg API expansion is the single largest contributor to this increase. If these timelines hold, the structural supply-demand imbalance that caused the 2022 to 2024 shortage should resolve, though regional and dose-specific disruptions may continue intermittently through 2026.

Prescribers should verify real-time availability at their patient's preferred pharmacy before writing new Ozempic prescriptions, and all patients with type 2 diabetes on semaglutide should have a documented backup GLP-1 agonist plan in their chart.